Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

Higher immune expression correlates with improved overall survival in metastatic CRC patients receiving anti-EGFR therapy.
The analysis reveals significant differences in survival outcomes based on tumor region and treatment arm.
Data were evaluated from patients undergoing maintenance therapy in the PanaMa trial with RAS wt metastatic CRC.
The findings highlight the potential for the immune microenvironment to serve as a prognostic and predictive biomarker.

Analysis shows overall survival differences based on immune expression and treatment arm in metastatic CRC patients, indicating possible biomarkers.

Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.

No takes yet. Share an insight, caveat, or question.

Ballhausen et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share